Bracco boosts nuclear medicine line with purchase:
This article was originally published in Clinica
Italian company Bracco is to strengthen its nuclear medicine business through the acquisition of the products and intellectual property from Resolution Pharmaceutical. Resolution, a private Canadian company, specialises in diagnosis, staging and treatment of neoplasias. "Not only does this acquisition broaden our pipeline of new potential products for diagnosis and therapy of tumours, but it also significantly strengthens our patent portfolio," said Michael Tweedle, president of Bracco Research USA.